Heart Test Laboratories (NASDAQ:HSCS) Receives “Buy” Rating from Maxim Group

Heart Test Laboratories (NASDAQ:HSCS)‘s stock had its “buy” rating reissued by analysts at Maxim Group in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $12.00 price objective on the stock. Maxim Group’s price target suggests a potential upside of 204.57% from the company’s current price.

Separately, Ascendiant Capital Markets reiterated a “buy” rating and issued a $15.00 price objective on shares of Heart Test Laboratories in a report on Monday, September 23rd.

Heart Test Laboratories Price Performance

Shares of NASDAQ:HSCS opened at $3.94 on Wednesday. The company has a quick ratio of 4.02, a current ratio of 4.49 and a debt-to-equity ratio of 0.08. The stock has a market cap of $3.60 million, a PE ratio of -0.19 and a beta of 3.23. The company’s fifty day moving average is $3.24 and its 200 day moving average is $3.79. Heart Test Laboratories has a 52 week low of $2.36 and a 52 week high of $18.50.

Heart Test Laboratories (NASDAQ:HSCS) last released its quarterly earnings data on Monday, December 16th. The company reported ($2.27) EPS for the quarter, topping the consensus estimate of ($2.30) by $0.03. During the same period in the previous year, the company posted ($15.92) earnings per share. Research analysts anticipate that Heart Test Laboratories will post -9.82 earnings per share for the current year.

Heart Test Laboratories Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.